Metformin: Hype or Hope for Cancer

dc.contributor.authorNar, Asli
dc.contributor.orcID0000-0003-0998-8388en_US
dc.contributor.researcherIDAAA-2743-2021en_US
dc.date.accessioned2019-05-28T23:08:29Z
dc.date.available2019-05-28T23:08:29Z
dc.date.issued2017
dc.description.abstractCurrent studies show that especially pancreatic, liver, endometrial, colorectal, bladder and breast cancer incidences are increased by the presence of type 2 diabetes mellitus (T2DM). Possible links between T2DM and cancer include hyperinsulinemia, dysregulation of adipocytokines and hyperglycemia as well as shared confounding risk factors. There is evidence emerging from experimental and clinical studies that metformin can play a crucial anti-cancereous role. Since 2005, multiple studies showed the association between metformin and the reduction of risk in cancers of pancreas, colorectal, stomach, liver, breast and esophagus in diabetes cases. It was also claimed to improve survival in some cancers. Metformin is an insulin sensitizer and mainly acts through inhibiting hepatic gluconeogenesis by activating LKB1/AMP-activated protein kinase (AMPK). Metformin was found to have anti-cancerous and anti-metastatic effects mainly through activating AMPK dependent and independent signaling; inhibiting mTOR, MAPK, HER2, NF-kappa B, IGF signaling pathways and with its possible immuno-modulatory effects. Further studies are needed to evaluate the potential of metformin as adjuvant therapy for cancer especially in non-diabetic patients.en_US
dc.identifier.endpage266en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85040015685en_US
dc.identifier.startpage258en_US
dc.identifier.urihttp://www.uhod.org/pdf/PDF_764.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3345
dc.identifier.volume27en_US
dc.identifier.wos000419586300009en_US
dc.language.isoengen_US
dc.relation.isversionof10.4999/uhod.171870en_US
dc.relation.journalUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISIen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectCanceren_US
dc.subjectMetforminen_US
dc.titleMetformin: Hype or Hope for Canceren_US
dc.typereviewen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PDF_764.pdf
Size:
344.57 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: